



Prostatype® P-score and prognostic evaluation in Prostate cancer to be presented at AUA, one of the world's leading Urology events

-Results of the study from Uppsala University Hospital ("Akademiska") selected to present during American Urology Association annual meeting 2022, taking place in New Orleans on May 13-16th.

The American Urology Association congress 2022 is one of the largest and most important gathering of Urologists in the world, and Prostatype Genomics is very proud to share that one of our Prostatype® clinical validation studies, whose preliminary results were first shared in August 2021, have been selected for presentation at the congress.

Fredrik Persson, CEO of Prostatype Genomics, comments "We are very happy to have received this nomination, over- and under- treatment of prostate cancer patients is common, and a big problem for healthcare in general, and most of all for the patients. To present and discuss Prostatype® and the P-score in front of the world's leading urologists is a great opportunity to help optimize prostate cancer risk assessment".

Study from Uppsala University Hospital

The purpose of the study, led by associate professor Michael Häggman at the Urology Clinic, Akademiska sjukhuset, Uppsala, Sweden was to show whether the result from the deployment of Prostatype® before making treatment decision for patients with prostate cancer corresponds to the actual level of aggressiveness of the tumour.

The first aim was whether the gene test Prostatype® and its associated algorithm P-score in fusion led biopsies are correlated to P-score in paired surgically removed prostates, so called prostatectomy specimens.

The second aim relates to the correlation between the P-score in the index tumour itself relative to that of concomitant non-index tumour areas in the prostatectomy specimens. The preliminary results show a high degree of correlation in P-score values (0.83-0.84) for both aims, which is further underlined by the strong statistical significance shown in both cases ($p < 0.0001$). This means that the test results from the tissue samples using Prostatype® provide the indication that is requested in order to make the decision on next step in treatment with greater certainty.

US market opportunity

The US market is as previously communicated one of Prostatype Genomics strategic priorities, and plans for the U.S. expansion are currently being finalized.

"Being chosen to present our company and results as well as to meet with leading American stakeholders at the largest urology congress in the U.S. will give us a unique opportunity for the best possible entry on this huge market", Fredrik Persson comments.

This disclosure contains information that Prostatype Genomics AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 11-01-2022 12:02 CET.

Nicklas Rosendal

Press contact

nicklas.rosendal@prostatypegenomics.com

Certified Advisor

Svensk Kapitalmarknadsgranskning AB, 011-32 30 732, ca@skmg.se

Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.